MAIA_logo_PNG_teal.png
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
22 févr. 2024 10h30 HE | MAIA Biotechnology, Inc.
Topline data expected in second half of 2024THIO-101 will be the first completed clinical study of a telomere targeting agent in the field of cancer drug discovery and treatment CHICAGO, IL, Feb. ...
TIP_link_300x300.jpg
Lung Cancer Therapy Market Share Worth $80.49 Billion, Globally, by 2030 - Exclusive Report by The Insight Partners
01 nov. 2023 06h46 HE | The Insight Partners
Pune, India, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Lung cancer now a days is treated by targeted therapy, a type of personalized medicine, is a combination of two or more drugs, designed to directly...
Logo.png
Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers
03 oct. 2023 08h01 HE | Ocean Biomedical, Inc.
Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on Pioneering Anti-CHI3L1 Discoveries Providence, RI, Oct. 03, 2023 (GLOBE...
youtube profile pic.png
Non-Small Cell Lung Cancer Market to Surpass 76.33 Billion by 2030 Drives Due to Rising Incidence of Non-Small Cell Lung Cancer Diagnoses
28 août 2023 09h30 HE | SkyQuest Technology Consulting Pvt. Ltd.
Westford, USA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- According to SkyQuest, the trajectory of the non-small cell lung cancer market is poised for advancement, propelled by a noteworthy trend – the...
ImPact Biotech receives FDA Clearance for Padeliporfin VTP Phase 1 Clinical Program in Peripheral Lung Cancer
04 août 2023 10h49 HE | ImPact Biotech
Padeliporfin VTP Phase 1 trial in Peripheral Non-Small Cell Lung Cancer to start by end Q4 2023 TEL AVIV, Israel, Aug. 04, 2023 (GLOBE NEWSWIRE) --  ImPact Biotech,...
Logo.png
PD-1 Non-Small Cell Lung Cancer Clinical Trials Pipeline Analysis: 20+ Companies are Working to Improve the Treatment Space | DelveInsight
20 juin 2023 13h00 HE | DelveInsight Business Research LLP
New York, USA, June 20, 2023 (GLOBE NEWSWIRE) -- PD-1 Non-Small Cell Lung Cancer Clinical Trials Pipeline Analysis: 20+ Companies are Working to Improve the Treatment Space | DelveInsight The...
abvc-logo-nasdaq-440x386 (1).png
FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment of Non-Small Cell Lung Cancer
05 janv. 2023 08h30 HE | ABVC BioPharma, Inc.
FREMONT, CA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
Future Market Insights.png
Non-Small Cell Lung Cancer Market Value to reach US$ 20 Billion by 2033, Experiencing 2X Growth across the Coming Decade: Future Market Insights, Inc. Report NEWARK, Del, Dec. 29, 2022 (GLOBE NEWSWIRE) -- A recently published study by FMI expects the global Non-small cell lung cancer market to augment at a 7.2% CAGR from 2023 to 2033. By the end of the...
logo 600X600.png
Global Non-small Cell Lung Cancer Treatment Market to Surpass US$ 50,962.7 Million by 2030, Says Coherent Market Insights (CMI)
11 oct. 2022 09h15 HE | CMI
Seattle, Oct. 11, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global non-small cell lung cancer treatment market is estimated to be valued at US$ 24,910.7 million in 2022 and...
GD_Black_Logo-01 160222.png
Merck & Co., Roche, and BMS Among Leading Players in the Non-Small Cell Lung Cancer Drugs Market | GlobalData Plc
20 juil. 2022 09h45 HE | GlobalData Plc
LONDON, July 20, 2022 (GLOBE NEWSWIRE) -- The “Non-Small Cell Lung Cancer (NSCLC) – Global Drug Forecast and Market Analysis to 2029” report offered by GlobalData provides an overview of NSCLC...